Career Enhancement Program
Career Enhancement Program
批准号:
10270585
负责人:
KEVIN M. SHANNON
金额:
$9.02万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-09-01 至 2026-08-31
关键词:
AccelerationAddressAreaAwardBasic ScienceCaliforniaCancer BiologyCancer CenterChildClinicalClinical InvestigatorClinical SciencesCommunicationCommunitiesDataDevelopmentDisciplineDiseaseEducationEnsureExtramural ActivitiesFacultyFeedbackFoundationsFundingFunding OpportunitiesFutureGoalsHealth SciencesHistorically Black Colleges and UniversitiesHumanHuman DevelopmentIndianaIndividualInfrastructureInstitutionInternationalKnowledgeLeadershipLinkMalignant NeoplasmsMemorial Sloan-Kettering Cancer CenterMentorsMentorshipMissionMonitorMutationNF1 geneNF1 mutationNational Cancer InstituteNatureNeurofibromatosesPathologyPediatric HospitalsPediatric OncologyPediatric Oncology GroupPhiladelphiaPre-Clinical ModelProcessProfessional OrganizationsProgram DevelopmentRequest for ApplicationsResearchResearch PersonnelResourcesRoleSan FranciscoScheduleScienceScientistSex OrientationSignal TransductionSiteSocietiesStructureTalentsTexasTextilesTherapeuticTherapeutic TrialsTrainingTraining ProgramsTranslational ResearchUnderrepresented MinorityUnderrepresented PopulationsUniversitiesWorkanticancer researchbasecancer therapycareercareer developmentclinical outcome assessmentclinical translationdesigndevelopmental diseasedisabilityearly-career facultyeffective therapyefficacy validationfaculty supporthyperactive Rasinnovationinstructormeetingsmemberminority investigatorneoplasm therapyneuro-oncologynext generationpharmacokinetics and pharmacodynamicspreclinical studyprofessorprogramsracial and ethnicrecruitsenior facultyskillssuccesstranslational scientisttumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT– CAREER ENCHANCEMENT PROGRAM
The DHART SPORE Career Enhancement Program (CEP) supports faculty at the Instructor and Assistant
Professor levels to engage in translational research focused on NF1/Rasopathy disorders and cancer. The
primary goal of the CEP is to advance the careers of early stage investigators who are developing innovative
research related to the goal of implementing more effective and less toxic therapies for cancers characterized
by NF1/Ras. The multi-institutional nature of this SPORE leverages a large and talented pool of early career
faculty from multiple disciplines. Each institution views the CEP as a vehicle for recruiting and advancing the
careers of early stage translational scientists. Collectively, they have committed $1.3 million to the current
award and $1.65 million to the renewal to support the Developmental Programs of the DHART SPORE (CEP
and DRP). The Specific Aims of the CEP are to: (1) support early stage investigators as they develop
innovative research programs that contribute new knowledge to NF1-related cancer research while generating
preliminary data that will allow successful future independent extramural funding; (2) provide early stage
researchers with training that will equip them with essential skills and knowledge for success as independent
investigators; and, (3) mentor early stage translational researchers through regularly scheduled one-on-one
mentor meetings and a structured Individual Development Program (IDP) to facilitate integration into the fabric
of the SPORE. The CEP has a special emphasis on supporting the recruitment of underrepresented minority
investigators (URM). The DHART SPORE will link vertically and horizontally with diversity programs at all of
the consortium institutions and ensure maximum exposure of the CEP mentorship and funding opportunities to
URM across the seven DHART SPORE sites. Further, requests for applications (RFA) will be shared with
Historically Black Colleges and Universities and professional organizations representing communities under-
represented in biomedical science. RFAs are already sent outside of the DHART SPORE sites via the
Children’s Tumor Foundation and Neurofibromatosis Therapeutic Acceleration Program. We are expanding
this recruitment effort to include the Society for Neuro-Oncology, RASopathies Network USA, the Children’s
Oncology Group. The goal is to fund two CEP proposals per year ($50,000 - $75,000/proposal). Requests for
applications will be announced twice a year via broad communications to all groups listed above to maximize
opportunities for recruitment of diverse scientists and science. CEP opportunities will also be highlighted at
professional meetings throughout the year. Applications for CEP support will be evaluated through a
competitive process with review by a Developmental Programs Steering Committee comprised of senor
scientists from the DHART SPORE with oversight and guidance from the SPORE External and Internal
Advisory Boards.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In Vivo Functional Analysis of Chromosome 7q22 Deletions in Myeloid Malignancies
-
批准号:9924474
-
项目类别:
-
资助金额:$33.87万
-
财政年份:2017
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:10372214
-
项目类别:
-
资助金额:$50.61万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Project 3: Efficacy of MEK Inhibition in Juvenile Myelomonocytic Leukemia
-
批准号:8932164
-
项目类别:
-
资助金额:$43.13万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:10209682
-
项目类别:
-
资助金额:$53.18万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Developmental Research Program
-
批准号:8932166
-
项目类别:
-
资助金额:$10.45万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:9040123
-
项目类别:
-
资助金额:$55.05万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:10610346
-
项目类别:
-
资助金额:$50.61万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Career Enhancement Program
-
批准号:10494113
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Developmental Research Program
-
批准号:10494111
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Career Development Program
-
批准号:8932167
-
项目类别:
-
资助金额:$10.45万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
PROJECT 3: A High Content Clinical Trial of the MEK inhibitor Trametinib in JMML
-
批准号:10270583
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
PROJECT 3: A High Content Clinical Trial of the MEK inhibitor Trametinib in JMML
-
批准号:10494109
-
项目类别:
-
资助金额:$37.55万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:9278130
-
项目类别:
-
资助金额:$49.7万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Developmental Research Program
-
批准号:10270584
-
项目类别:
-
资助金额:$9.02万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:8895286
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:9112921
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:8590462
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:8735906
-
项目类别:
-
资助金额:$31.81万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
ID OF MOLECULES THAT SUBSTITUTE FOR ACTIVE NOTCH1 IN T LINEAGE LEUKEMOGENESIS
-
批准号:8363842
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2011
-
负责人:KEVIN M. SHANNON
-
依托单位:
Myeloid Tumor Suppressor Gene Discovery from Chromosome Band 7q22
-
批准号:8319537
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2011
-
负责人:KEVIN M. SHANNON
-
依托单位:
海外基金